CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)
Public ClinicalTrials.gov record NCT03163667. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to compare the progression-free survival (PFS) of participants treated with telaglenastat and everolimus versus placebo and everolimus for advanced or metastatic clear cell renal cell carcinoma (ccRCC) previously treated with the following: * At least 2 lines of therapy, including at least 1 vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) * Radiographic progression of metastatic RCC must have occurred (per investigator assessment) on or after the most recent systemic therapy and within 6 months prior to cycle 1 day 1
Study identification
- NCT ID
- NCT03163667
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 69 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 6, 2017 (Actual)
- Primary completion
- Apr 26, 2019 (Actual)
- Completion
- Jun 1, 2020 (Actual)
- Last update posted
- Sep 15, 2022
2017 – 2020
United States locations
- U.S. sites
- 38
- U.S. states
- 25
- U.S. cities
- 37
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| Highlands Oncology Group | Rogers | Arkansas | 72758 | — |
| Los Angeles Hematology Oncology Medical Group | Los Angeles | California | 90017 | — |
| UCLA Department of Medicine - Hematology/Oncology | Los Angeles | California | 90095 | — |
| Stanford Cancer Center | Stanford | California | 94305 | — |
| Florida Cancer Specialists- South | Fort Myers | Florida | 33901 | — |
| Florida Cancer Specialists- North | St. Petersburg | Florida | 33705 | — |
| University Cancer & Blood Center, LLC | Athens | Georgia | 30607 | — |
| Northwest Georgia Oncology Centers, P.C. | Marietta | Georgia | 30060 | — |
| St. Luke's Mountain States Tumor Institute | Boise | Idaho | 83712 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Parkview Research Center | Fort Wayne | Indiana | 46845 | — |
| University of Iowa Hospitals and Clinics | Iowa City | Iowa | 52242 | — |
| Norton Cancer Institute, Norton Healthcare Pavilion | Louisville | Kentucky | 40202 | — |
| Ochsner Clinical Foundation | New Orleans | Louisiana | 70121 | — |
| Anne Arundel Medical Center Oncology and Hematology | Annapolis | Maryland | 21401 | — |
| University of Maryland, Greenebaum Comprehensive Cancer Center | Baltimore | Maryland | 21201 | — |
| Metro-Minnesota Community Oncology Research Consortium | Saint Louis Park | Minnesota | 55416 | — |
| Mercy Clinic Oncology & Hematology | Joplin | Missouri | 64804 | — |
| SCRI HCA Midwest | Kansas City | Missouri | 64132 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| St. Vincent Frontier Cancer Center | Billings | Montana | 59102 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89148 | — |
| North Shore Hematology Oncology Associates PC DBA NY Cancer and Blood Specialists | East Setauket | New York | 11733 | — |
| NYU Winthrop Hospital - Cancer Clinical Trials Oncology/Hematology | Mineola | New York | 11501 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| SUNY Upstate Medical University | Syracuse | New York | 13210 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45219 | — |
| Ann B. Barshinger Cancer Institute / Lancaster General Hospital | Lancaster | Pennsylvania | 17604 | — |
| Monongahela Valley Hospital | Monongahela | Pennsylvania | 15063 | — |
| Charleston Hematology Oncology Associates,PA | Charleston | South Carolina | 29414 | — |
| UT/Erlanger Oncology & Hematology | Chattanooga | Tennessee | 37403 | — |
| Sarah Cannon Research Institute - Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Utah Cancer Specialists | Salt Lake City | Utah | 84106 | — |
| Wenatchee Valley Hospital and Clinics | Wenatchee | Washington | 98801 | — |
| University of Wisconsin Carbone Cancer Center | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03163667, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 15, 2022 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03163667 live on ClinicalTrials.gov.